T2 Biosystems Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Craig Jalbert

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	3.3yrs
Durata media del Consiglio di amministrazione	3yrs

Aggiornamenti recenti sulla gestione

Recent updates

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

AMMINISTRATORE DELEGATO

Craig Jalbert (62 yo)

no data

Mandato

Mr. Craig R. Jalbert, CIRA is CEO, President, Corporate Treasurer, Corporate Secretary & Director of T2 Biosystems, Inc. from April 3, 2025. He is CEO, President, CFO, Treasurer, Corporate Secretary & Dire...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Craig Jalbert	CEO, President	no data	Nessun dato	Nessun dato
Kelley Morgan	Chief People Officer	11.1yrs	Nessun dato	Nessun dato
Brett Giffin	Chief Commercial Officer	3.4yrs	Nessun dato	0.00027% $ 8.3
Roger Smith	Senior Vice President of Science Research & Development	3.1yrs	Nessun dato	Nessun dato

3.3yrs

Durata media

60.5yo

Età media

Gestione esperta: Il team dirigenziale di TTOO è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Craig Jalbert	CEO, President	no data	Nessun dato	Nessun dato
Eric Rosenberg	Member of Clinical Advisory Board	13.9yrs	Nessun dato	Nessun dato
Louis Rice	Member of Clinical Advisory Board	13.9yrs	Nessun dato	Nessun dato
Michael Rybak	Member of Scientific Advisory Board	3yrs	Nessun dato	Nessun dato
James Snyder	Member of Scientific Advisory Board	3yrs	Nessun dato	Nessun dato
Ninfa Saunders	Independent Director	4.8yrs	US$50.00k	0.00026% $ 8.0
Thomas Walsh	Member of Scientific Advisory Board	3yrs	Nessun dato	Nessun dato
Peter Pappas	Member of Clinical Advisory Board	13.9yrs	Nessun dato	Nessun dato
Michael Pfaller	Member of Clinical Advisory Board	7.7yrs	US$1.10m	Nessun dato
Sean Zhang	Member of Scientific Advisory Board	3yrs	Nessun dato	Nessun dato
Denise Uettwiller-Geiger	Member of Scientific Advisory Board	3yrs	Nessun dato	Nessun dato
George Pankey	Member of Scientific Advisory Board	3yrs	Nessun dato	Nessun dato

3.0yrs

Durata media

72yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TTOO sono considerati esperti (durata media dell'incarico 3 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/04/30 09:58
Prezzo dell'azione a fine giornata	2025/04/30 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

T2 Biosystems, Inc. è coperta da 10 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Benjamin Haynor	Alliance Global Partners
Karen Koski	BTIG
Kyle Mikson	Canaccord Genuity

T2 Biosystems Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

T2 Biosystems, Inc. Announces CFO Changes

T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

Insufficient new directors

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

High number of new directors

Recent updates

T2 Biosystems, Inc. Announces CFO Changes

T2 Biosystems, Inc. announced delayed annual 10-K filing

T2 Biosystems, Inc. Approves Reduction-In-Force of Substantially All of Its Employees

T2 Biosystems, Inc. Approves Reduction-In-Force of Substantially All of Its Employees

T2 Biosystems, Inc.(OTCPK:TTOO) dropped from S&P TMI Index

T2 Biosystems, Inc.(OTCPK:TTOO) dropped from NASDAQ Composite Index

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

T2 Biosystems Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024

T2 Biosystems Receives Letter from the Nasdaq Regarding Listing Rule 5550(b)(2)

T2 Biosystems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

T2 Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter 2024

T2 Biosystems, Inc. Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

T2 Biosystems, Inc. to Report Q2, 2024 Results on Jul 29, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering in the amount of $14.658742 million.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering.

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient new directors

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

Consensus revenue estimates decrease by 21%, EPS upgraded

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Full year 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates decrease by 50%, EPS upgraded

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. has completed a Follow-on Equity Offering.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Consensus EPS estimates fall by 15%

Price target decreased to US$1.85

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022

T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million